Dr. Ulrich Storz

Ulrich Storz received his PhD from the University of Münster in 2002 with a thesis in neurobiology. 


He then completed his training to become a German patent attorney, and joined the list of professional representatives before the European Patent Office in 2006.


Dr. Storz's main areas of practice are managing and enforcing patents and patent applications as well as drafting FTO analyses and opinions. He also provides advice on strategic patent issues, notably in life sciences (biotechnology, biophysics, biochemistry and microbiology), above all in the field of therapeutic antibodies.


Ulrich Storz is regularly involved in major antibody opposition cases before the European Patent Office. He has also significant expertise in gene editing technologies including CRISPR, TALEN und ZFN, and also works in the field of CAR T cells, stem cell technologies, plant biosciences and enzymes.


In recent years, he has also provided representation in a large number of sizeable due diligence projects in the field of pharmaceuticals and life sciences with a volume of EUR 500,000 to EUR 100m.


"The rapid development of life sciences affects patent law issues, too. This is both a blessing and curse for IP lawyers — but it keeps things interesting at any rate."


Dr. Storz organizes the annual Rhineland Biopatent Forum and regularly publishes articles on patent issues relating to therapeutic antibodies in the magazine mAbs. He is a member of the Antibody Society, the Licensing Executive Society (LES), the Association for the Protection of Intellectual Property (GRUR) and the Association of Intellectual Property Experts (VPP).


Ulrich Storz was born in Münster, Germany in 1969 and now lives with his family in the Rhineland, halfway between Cologne and Düsseldorf. He speaks German, English and French fluently. His hobbies include mountain biking and sailing, and every once in a while, he picks up the guitar.



"Ulrich’s work was a substantial element in Molecular Partners’ successful IPO. He knows how to generate value."

Patrik Forrer, co-founder and former VP Intellectual Property of Molecular Partners AG


"Ulrich has represented NBE Therapeutics from the very beginning to the day of its acquisition by Boehringer Ingelheim. He was responsible for providing strategic IP counsel, as well as drafting, filing and prosecuting the entire IP portfolio, and successfully carried out FTO analyses, third party observations and oppostions. Ulrich’s support was key for NBE’s value creation. His legal and technical expertise is unparalleled."

Ulf Grawunder, founder and CEO of NBE Therapeutics


"Ulrich is a puncher in opposition proceedings, and has excellent success rates. We would not want to have him against us."

n/a, medium sized biotech company


“Michalski Hüttermann (…) are among the best-known patent law firms for biotech patents in Germany”


"Cases concerning therapeutic antibodies at the EPO are likely to carry Ulrich Storz's name."


Mentioned as an IP Star in MIP Handbook